SciELO - Scientific Electronic Library Online

 
vol.20 número1Giant renal tumor with inferior vena cava thrombus - a case reportFenestrated Physician-Modified Endografts (PMEGs) - a viable option for urgent cases índice de autoresíndice de assuntosPesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Não possue artigos similaresSimilares em SciELO

Compartilhar


Angiologia e Cirurgia Vascular

versão impressa ISSN 1646-706X

Resumo

GUEIFAO, Inês et al. Targeted therapy with sirolimus in vascular malformations - a case report. Angiol Cir Vasc [online]. 2024, vol.20, n.1, pp.35-37.  Epub 18-Maio-2024. ISSN 1646-706X.  https://doi.org/10.48750/acv565.

Background:

Vascular malformations are a heterogeneous group of vascular development disorders with historically few treatment options. Recent studies have shown the potential benefit of mTOR inhibitors-such as sirolimus-in their treatment, particularly in low-flow malformations. However, reports on their efficacy in high-flow malformations are scarce and controversial. We report the case of a patient with a combined malformation who benefited from treatment with sirolimus.

Report:

A three-year-old patient was referred to our center with a diffuse and progressive vascular malformation on her right leg, difficult to classify according to ISSVA, with disabling pain, limb deformity, and walking impairment. The initial MRI showed a diffuse malformation on the deep subcutaneous tissue without muscle or bone involvement, measuring 18cm on the largest axis. A progressive clinical worsening occurred, and after discussion with an international reference center in vascular malformations, it was classified as a diffuse vascular malformation with the involvement of contiguous structures without defined borders, with both a low and high-flow component. The high-flow component now behaves like a type IV Yakes AVM. Nevertheless, long-term therapy with sirolimus was instituted when the patient was nine years old, resulting in complete remission of pain, recovery of walking ability, and partial recovery of knee valgus. No side effects were reported. With 38 months of follow-up, the 13-year-old remains pain-free and has improved quality of life despite no imagological improvement.

Conclusion:

Although the available evidence for mTOR inhibitors is mainly for low-flow malformations, it may be a safe and effective option for selected high-flow malformations when intervention is not possible or carries significant morbidity risks. Some studies showed a reduction in the size of the malformation with treatment; however, this was not the case in our patient, notwithstanding the clear improvement in quality of life for four years without other intervention.

Palavras-chave : Vascular malformations; high-flow malformations; mTOR inhibitors; sirolimus.

        · texto em Inglês     · Inglês ( pdf )